At our center, the panel was expanded in 2022 to identify PVs in moderate-penetrance genes, such as CHEK2, ATM, RAD51C, RAD51D, and BARD1 (approx. 20–40% lifetime risk for breast cancer), as well as the so-called syndromic genes, PTEN, STK11, and TP53, which are associated with other specific manifestations [1]. Here, BARD1 is linked to breast carcinoma.